EGFR and hepatocellular carcinoma: The combination of the EGFR inhibitor gefitinib and lenvatinib has strong anti-proliferative effects in xenografted liver cancer cells, immunocompetent animal models, patient-derived HCC tumors in mouse models, and liver cancer cell lines that express EGFR.